GBT - グロ―バル・ブラッド・セラピュ―ティクス （Global Blood Therapeutics Inc.）

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease (SCD). The acquisition reinforces Pfizer’s commitment to SCD, building on a 30-year legacy in the rare hematology space. GBT brings a portfolio and pipeline tha

Global Blood Therapeutics (GBT) expects to consummate its $5.4B deal with Pfizer (PFE) on Oct. 5, the sickle cell disease drugmaker said in a regulatory filing on Friday

Global Blood Therapeutics has several intriguing molecules that could garner blockbuster sales for Pfizer in the coming years. Read what investors need to know.

Global Blood Therapeutics Inc. (NASDAQ:GBT) price on Friday, September 09, fall -0.01% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $67.97. A look at the stock’s price movement, the level at last check in today’s session was $67.98, moving within a range at $67.70 and $67.99. The … Analysts Predicting A Spike In Global Blood Therapeutics Inc. (NASDAQ: GBT)? Read More »

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease (SCD). The acquisition reinforces Pfizer’s commitment to SCD, building on a 30-year legacy in the rare hematology space. GBT brings a portfolio and pipeline tha

Global Blood Therapeutics (GBT) expects to consummate its $5.4B deal with Pfizer (PFE) on Oct. 5, the sickle cell disease drugmaker said in a regulatory filing on Friday

Global Blood Therapeutics has several intriguing molecules that could garner blockbuster sales for Pfizer in the coming years. Read what investors need to know.

Global Blood Therapeutics Inc. (NASDAQ:GBT) price on Friday, September 09, fall -0.01% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $67.97. A look at the stock’s price movement, the level at last check in today’s session was $67.98, moving within a range at $67.70 and $67.99. The … Analysts Predicting A Spike In Global Blood Therapeutics Inc. (NASDAQ: GBT)? Read More »

Global Blood Therapeutics (NASDAQ: GBT ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 These 4 analysts have an average price target of $56.5 versus the current price of Global Blood Therapeutics at $29.15, implying upside. Below is a summary of how these 4 analysts rated Global Blood Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive … Full story available on Benzinga.com

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences:

GBT earnings call for the period ending December 31, 2021.

Global Blood Therapeutics press release (GBT): Q4 GAAP EPS of -$1.36 misses by $0.23.Revenue of $56.1M (+35.8% Y/Y) beats by $0.65M.Cash, cash equivalents, and marketable…